Aspirin in the aetiology of Crohn's disease and ulcerative colitis: A European prospective cohort study

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 6, 2011, Pages 649-655

  Chan, S S M ^a,h   Luben, R ^b   Bergmann, M M ^c   Boeing, H ^c   Olsen, A ^d   Tjonneland, A ^d   Overvad, K ^e   Kaaks, R ^f   Kennedy, H ^a   Khaw, K T ^b   Riboli, E ^g   Hart, A R ^a,h  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; COHORT ANALYSIS; CROHN DISEASE; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS;

EID: 80052030390     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04784.x     Document Type: Article

References (29)

1. Irvine EJ,. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008; 14: 554-65. (Pubitemid 351571837)
2. Eaden J,. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 24-30. (Pubitemid 39319243)
3. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A,. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
4. Visiongain. Inflammatory Bowel Disease: World Market 2010-2025 London, 2010.
5. Langman MJ,. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology 1989; 2 (Suppl.): 640-6. (Pubitemid 19038540)
6. Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD,. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 2007; 26: 95-106. (Pubitemid 46889838)
7. Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-53. (Pubitemid 27428194)
8. Somasundaram S, Sigthorsson G, Simpson RJ, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 2000; 14: 639-50. (Pubitemid 30240758)
9. Loll PJ, Picot D, Garavito RM,. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-43.
10. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN,. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2: 612-9. (Pubitemid 32677628)
11. Miles EA, Allen E, Calder PC,. In vitro effects of eicosanoids derived from different 20-carbon fatty acids on production of monocyte-derived cytokines in human whole blood cultures. Cytokine 2002; 20: 215-23. (Pubitemid 37163474)
12. Hatoum OA, Gauthier KM, Binion DG, et al. Novel mechanism of vasodilation in inflammatory bowel disease. Arterioscler Thromb Vasc Biol 2005; 25: 2355-61. (Pubitemid 41552654)
13. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM,. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997; 40: 619-22. (Pubitemid 27278329)
14. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G,. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000; 95: 1949-54.
15. Gleeson MH, Davis AJ,. Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study. Aliment Pharmacol Ther 2003; 17: 817-25. (Pubitemid 36418879)
16. Calkins BM,. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-54. (Pubitemid 20018648)
17. Bonner GF, Walczak M, Kitchen L, Bayona M,. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 1946-8. (Pubitemid 30629291)
18. Mahadevan U, Loftus EV Jr., Tremaine WJ, Sandborn WJ,. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 910-4. (Pubitemid 34408247)
19. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5: 1040-5.
20. Meyer AM, Ramzan NN, Heigh RI, Leighton JA,. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006; 51: 168-72. (Pubitemid 43106356)
21. Serhan CN, Chiang N, Van Dyke TE,. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-61. (Pubitemid 351595216)
22. Jing H, Vassiliou E, Ganea D,. Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol 2003; 74: 868-79. (Pubitemid 38040363)
23. Kunkel SL, Wiggins RC, Chensue SW, Larrick J,. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun 1986; 137: 404-10. (Pubitemid 16056080)
24. Xu XJ, Reichner JS, Mastrofrancesco B, Henry WL Jr., Albina JE,. Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. J Immunol 2008; 180: 2125-31.
25. Pons F, Williams TJ, Kirk SA, McDonald F, Rossi AG,. Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue, ZK 118.182. Eur J Pharmacol 1994; 261: 237-47. (Pubitemid 24267968)
26. Rajakariar R, Hilliard M, Lawrence T, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A 2007; 104: 20979-84.
27. Angerson WJ, Allison MC, Baxter JN, Russell RI,. Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease. Gut 1993; 34: 1531-4. (Pubitemid 23341842)
28. Wallace JL, McKnight W, Reuter BK, Vergnolle N,. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 706-14.
29. Hatoum OA, Binion DG, Otterson MF, Gutterman DD,. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125: 58-69. (Pubitemid 36799107)